Get started
Author

Hana Vakil

Observed name: H Vakil
ORCID: 0009-0008-1288-9165
Observed ORCID: 0009-0008-1288-9165
OpenAlex ID: A5066501377
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
2012 · Frank S Ong, Kingshuk Das, et al. · Expert Review of Molecular Diagnostics · 96
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · JCO Precision Oncology · 37
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
2023 · Scott A. Tomlins, Nickolay A. Khazanov, et al. · Communications Medicine · 31
PDF
Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test
2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · Journal of Molecular Diagnostics · 24
The M694V mutation in Armenian‐Americans: a 10‐year retrospective study of MEFV mutation testing for familial Mediterranean fever at UCLA
2012 · FS Ong, H Vakil, et al. · Clinical Genetics · 14
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al. · Cancer Research Communications · 12
PDF
PCR-based comprehensive genomic profiling (PCR-CGP): Feasibility from >20,000 tumor tissue specimens (TTS) and predicted impact on actionable biomarker identification versus hybrid capture (H)-CGP and plasma (P)-CGP.
2020 · Dan Rhodes, Daniel H Hovelson, et al. · Journal of Clinical Oncology · 1
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
2024 · Brandi Oakley, Justin Moon, et al. · Journal of Thoracic Oncology
PDF
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S7 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Figure S6 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S8 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Table S11 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Table S3 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S6 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Works count: 78
Citation count: 215
H-index: 6
I10-index: 6
Year
Topic
Type